Clover Biopharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Cash & Equivalents	380.94	401.24	735.86	1,607	2,767	516.18	Upgrade
Short-Term Investments	-	-	2.94	2.94	61.09	270.33	Upgrade
Trading Asset Securities	14.8	14.78	14.17	13.93	30.91	-	Upgrade
Cash & Short-Term Investments	395.74	416.02	752.97	1,624	2,859	786.51	Upgrade
Cash Growth	-17.72%	-44.75%	-53.64%	-43.19%	263.55%	395.62%	Upgrade
Accounts Receivable	2.16	40.99	24.11	-	-	-	Upgrade
Other Receivables	-	24.21	49.6	-	-	-	Upgrade
Receivables	2.16	65.21	73.71	-	-	-	Upgrade
Inventory	11.76	11.03	696.98	2,384	768.69	50.88	Upgrade
Restricted Cash	9.7	11.5	13.29	16.3	6.8	20	Upgrade
Other Current Assets	40.43	159.44	362.58	365.01	1,442	191.03	Upgrade
Total Current Assets	459.79	663.21	1,900	4,390	5,076	1,048	Upgrade
Property, Plant & Equipment	103.99	116.18	162.06	241.74	222.4	86.99	Upgrade
Other Intangible Assets	30.43	33.35	39.86	35	13.83	0.28	Upgrade
Other Long-Term Assets	-	-	-	28.04	32.93	51.84	Upgrade
Total Assets	594.21	812.74	2,101	4,695	5,346	1,188	Upgrade
Accounts Payable	111.15	120.45	247.83	856.96	588.56	34.76	Upgrade
Accrued Expenses	-	42.26	70.62	88.47	96.9	25.69	Upgrade
Short-Term Debt	-	73.97	308.06	294.06	-	-	Upgrade
Current Portion of Leases	11.99	12.18	18.54	23.57	21.48	4.26	Upgrade
Current Unearned Revenue	1,588	1,612	1,578	1,555	1,424	-	Upgrade
Other Current Liabilities	52.55	46.35	54.11	10.84	17.62	2.03	Upgrade
Total Current Liabilities	1,764	1,908	2,277	2,829	2,148	66.73	Upgrade
Long-Term Debt	-	-	-	-	-	1,127	Upgrade
Long-Term Leases	1.06	3.5	7.85	36.74	46.44	18.06	Upgrade
Long-Term Unearned Revenue	25.3	25.3	44.36	2,497	1,932	958.17	Upgrade
Other Long-Term Liabilities	510.46	512.58	505.05	-	-	-	Upgrade
Total Liabilities	2,300	2,449	2,834	5,363	4,127	2,170	Upgrade
Common Stock	0.84	0.84	0.84	0.84	0.74	-	Upgrade
Additional Paid-In Capital	8,659	8,654	8,621	8,562	7,972	-	Upgrade
Retained Earnings	-10,645	-10,544	-9,640	-9,502	-7,050	-1,034	Upgrade
Treasury Stock	-0.02	-0.03	-0.03	-0.04	-0.05	-	Upgrade
Comprehensive Income & Other	278.59	252.84	285.85	270.38	296.63	50.78	Upgrade
Shareholders' Equity	-1,706	-1,636	-732.83	-668.14	1,219	-982.74	Upgrade
Total Liabilities & Equity	594.21	812.74	2,101	4,695	5,346	1,188	Upgrade
Total Debt	13.05	89.64	334.45	354.37	67.92	1,150	Upgrade
Net Cash (Debt)	382.7	326.38	418.52	1,270	2,791	-363.11	Upgrade
Net Cash Growth	53.16%	-22.02%	-67.04%	-54.51%	-	-	Upgrade
Net Cash Per Share	0.30	0.26	0.34	1.15	2.41	-0.48	Upgrade
Filing Date Shares Outstanding	1,297	1,297	1,296	1,293	1,158	1,158	Upgrade
Total Common Shares Outstanding	1,297	1,297	1,296	1,293	1,158	-	Upgrade
Working Capital	-1,304	-1,244	-377.48	1,561	2,928	981.69	Upgrade
Book Value Per Share	-1.32	-1.26	-0.57	-0.52	1.05	-	Upgrade
Tangible Book Value	-1,737	-1,670	-772.69	-703.14	1,205	-983.02	Upgrade
Tangible Book Value Per Share	-1.34	-1.29	-0.60	-0.54	1.04	-	Upgrade
Buildings	-	-	29.8	29.75	29.75	-	Upgrade
Machinery	-	-	147.25	128.37	101.65	28.48	Upgrade
Construction In Progress	-	-	25.28	44.08	32.15	38.29	Upgrade
Leasehold Improvements	-	-	35.79	31.6	11.38	6.06	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.